Approximately 2% of the patients screened in our laboratories with activated partial
thromboplastin times are found to have a lupus anticoagulant. Recognition of lupus …

With the well-documented association of lupus anticoagulants with thrombotic disease and
recurrent spontaneous abortion, the laboratory approach to diagnosing these inhibitors is …

The sensitivity and responsiveness of seven activated partial thromboplastin time reagents
to the presence of lupus anticoagulants (LAs) was evaluated with a panel of 50 well …

Circulating anticoagulants or inhibitors of clotting factors are defined as endogenously
produced substances that interfere with various in vitro tests of coagulation. 1 Anticoagulants …

Clinical and laboratory features were evaluated in 48 patients with lupus anticoagulants and
the efficiency of three different assays in the detection of lupus anticoagulants was …

The lupus inhibitor is an autoantibody with anticoagulant properties, and is found in a high
proportion of patients with'systemic lupus eryth-ematosus (SLE) as well as in patients with a …

The introduction of the activated partial thromboplastin time (APTT) as a screening test has
resulted in increased recognition of circulating anticoagulants. The most frequently …

To define clinical and laboratory characteristics of the lupus anticoagulant (LA), we reviewed
our experience (219 subjects). Subjects were divided into group A, those with the LA and the …

Fourteen male patients examined for a prolonged partial thromboplastin time were found to
have the lupus anticoagulant. In contrast to previous reports, there was no increased …

An acquired inhibitor of blood coagulation, similar to that described in patients with Systemic
Lupus Erythematosus (SLE), was detected during routine coagulation screening in 10 …